BridgeMD
Compares treatment options for Cirrhosis
Official title Hepatic Venous Pressure Gradient Versus Endoscopic Ultrasound-Guided Portal Pressure Gradient - Comparative Analysis (HEPCA)
ClinicalTrials.gov ID: NCT07424963
What this study is testing
- What it's testing
- The goal of this interventional trial is to compare in measuring of portal hypertension by HVPG and EUS-PPG in subject indicated to HVPG measurement. The primary question is whether EUS-PPG provides measurements really equivalent to HVPG in terms of gradient accuracy.
- This is a blinded study.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Age 18-75 years at the time of enrollment; signed informed consent
- Clinical indication for HVPG measurement and/or transjugular liver biopsy for chronic advanced liver disease
You likely can't join if
- Severe co-morbidities (e.g., advanced chronic heart failure, chronic renal insufficiency stage 4 and above, long-term poorly compensated diabetes...
- Pregnancy
- Estimated patient non-compliance and/or not signing of the informed consent
- Documented iodine contrast dye allergy
- Presence of portal vein thrombosis or cavernomatous transformation of portal vein or hepatic vein obstruction
- Ascites Grade 3
See the full eligibility criteria
- Age 18-75 years at the time of enrollment; signed informed consent
- Clinical indication for HVPG measurement and/or transjugular liver biopsy for chronic advanced liver disease
- Severe co-morbidities (e.g., advanced chronic heart failure, chronic renal insufficiency stage 4 and above, long-term poorly compensated diabetes mellitus with severe complications)
- Pregnancy
- Estimated patient non-compliance and/or not signing of the informed consent
- Documented iodine contrast dye allergy
- Presence of portal vein thrombosis or cavernomatous transformation of portal vein or hepatic vein obstruction
- Ascites Grade 3
- Biliary obstruction
- Anticoagulation or antiplatelet therapy, which cannot be discontinued
- INR \> 1.5 and/or platelet count \< 50,000/µl
- Hepatocellular carcinoma in the left lobe of the liver
- Surgically altered upper gastrointestinal tract anatomy
- State after transjugular intrahepatic portosystemic shunt
- State after liver transplantation
The study team makes the final eligibility decision.
Where it's taking place
- Prague, Bohemia, Czechia
- Prague, Czechia
Compensation & support
A stipend or compensation may be offered.
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Prague, Bohemia, Czechia; Prague, Czechia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.